Intercure (INCR) Stock Price, Financials & Analysis

Key Stats

Market Cap52.28 Mn

P/E-4.95

P/S0.67

Total Debt (Qtr)60.36 Mn

Add ratio to table…

About

InterCure Ltd. is an Israeli public corporation engaged in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use. The company operates licensed cultivation sites in Israel and maintains a network of pharmacies and distribution partners to supply its products to patients. In addition, InterCure Ltd. holds a non‑material biomed investment segment that focuses on strategic investments in life sciences and…

InterCure Ltd. generates revenue primarily from the sale of dried cannabis inflorescences and cannabis oil extracts to licensed pharmacies and distribution partners in Israel. The company also earns modest returns from its biomed investments through equity holdings and potential future milestones. Its products are sold under the CANNDOC brand and through partner brands such as Cookies, Givol, Leon Pharm and Max Pharm.

The company operates through the following segments:

Cannabis Production and Distribution: This segment encompasses the breeding, cultivation, processing, manufacturing and sale of pharmaceutical‑grade cannabis and cannabis‑based products for medical use, including the operation of the Northern and Southern facilities and the owned pharmacy chain.
Biomed Investments: This segment consists of strategic equity investments in life sciences and medical innovation companies, which currently represent a non‑material portion of overall activities.

InterCure Ltd. holds a leading position in the Israeli medical‑use cannabis market as one of the first licensed producers and a pioneer with over 18 years of operational experience. The company’s products meet IMCA‑certified IMC‑GAP, IMC‑GMP and IMC‑GDP standards, giving it a competitive advantage over rivals such as Aurora Cannabis Inc., Canopy Growth Corporation, Seah Medical Group, Village Farms Crop and Bedrocan International B. V. Strategic alliances with global players like Tilray, Organigram and Charlotte’s Web further strengthen its international footprint and access to complementary supply chains.

InterCure Ltd. serves licensed pharmacies, medical cannabis distributors and retail pharmacy chains across Israel. Specific customers include the Super‑Pharm pharmacy chain, Novolog, SLE, N. D. N., Pharma Zone and the company’s own pharmacy brands Givol™, Leon Pharm, Max Pharm and Cookies. The company also supplies products to international partners in the European Union and Canada pending regulatory approvals.

How Intercure ranks

Ranked against the 40 companies in Tobacco and Cannabis58 metrics · as of Oct 16, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −4.95xMedian 16.3x 58^th
P/FCF 61.9xMedian 23.8x 49^th
P/Operating cash flow —Median 11.4x No data —
P/S 0.67xMedian 0.92x 60^th
P/B 0.42xMedian 1.01x 89^th
P/Tangible book 0.42xMedian 1.08x 88^th
EV/EBITDA —Median 12.7x No data —
EV/EBIT —Median 18.3x No data —
EV/Revenue —Median 1.15x No data —
EV/FCF —Median 22.7x No data —
EV/Operating cash flow —Median 14.2x No data —
PEG (3Y EPS CAGR) —Median 0.51 No data —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) —Median 3.7% No data —
Revenue CAGR (3Y) —Median −0.6% No data —
Gross profit growth (1Y) —Median 2.2% No data —
Gross profit CAGR (3Y) —Median 3.2% No data —
Operating income growth (1Y) —Median −8.1% No data —
Operating income CAGR (3Y) —Median 27.2% No data —
Net income growth (1Y) —Median −9.3% No data —
Net income CAGR (3Y) —Median 21.8% No data —
EPS growth (1Y) —Median −8.5% No data —
EPS CAGR (3Y) —Median 25.1% No data —
Operating cash flow growth (1Y) —Median 14.4% No data —
Operating cash flow CAGR (3Y) —Median 12.1% No data —
Free cash flow growth (1Y) —Median 29.7% No data —
Free cash flow CAGR (3Y) —Median 26.8% No data —

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin —Median 43.3% No data —
EBITDA margin —Median 1.7% No data —
Operating margin —Median −6.4% No data —
Pretax margin —Median −14.1% No data —
Net margin —Median −16.1% No data —
FCF margin —Median 1.8% No data —
Operating cash flow margin —Median 5.1% No data —
Return on equity —Median −33.2% No data —
Return on assets —Median −13.4% No data —
Return on invested capital —Median −4.4% No data —
Return on capital employed —Median −3.0% No data —
Asset turnover —Median 0.59x No data —
Cash conversion (OCF / net income) —Median 1.18x No data —
Stock comp / revenue —Median 2.3% No data —

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 27.8%Median 22.4% 41^st
Debt / equity 0.48xMedian 0.40x 44^th
Net debt / EBITDA —Median 2.38x No data —
Debt / FCF —Median 2.86x No data —
Liabilities / assets 42.6%Median 67.5% 71^st
Equity / assets 57.4%Median 32.5% 71^st
Interest coverage —Median −2.88x No data —
Current ratio —Median 1.66x No data —
Quick ratio 0.96xMedian 0.69x 62^nd
Cash ratio 0.22xMedian 0.40x 22^nd
Altman Z-score —Median −1.20 No data —

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	PM	Philip Morris International Inc.	313.55 Bn	28.83	7.37	49.11 Bn
2	BTI	British American Tobacco p.l.c.	128.08 Bn	-	-	46.47 Bn
3	MO	Altria Group, Inc.	123.78 Bn	15.52	5.28	24.58 Bn
4	RLX	RLX Technology Inc.	2.10 Bn	35.44	3.00	0.02 Bn
5	CURLF	Curaleaf Holdings, Inc.	2.04 Bn	-63.89	1.56	0.61 Bn
6	TRLV	Trulieve Cannabis Corp.	1.98 Bn	-4.18	1.74	0.19 Bn
7	GTBIF	Green Thumb Industries Inc.	1.37 Bn	10.78	1.13	0.57 Bn
8	INCR	Intercure Ltd.	0.05 Bn	-4.95	0.67	0.06 Bn

Intercure INCR

About

How Intercure ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Intercure INCR

About

How Intercure ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password